CCM
BIOC

Connective Capital Management’s Biocept, Inc. BIOC Stock Holding History

Connective Capital Management’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,609
Closed -$57.4K – 59
2022
Q4 		$57.4K Buy
+3,609
New +$79.6K 0.02% 44

Other funds holding BIOC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TMWM
Taylor & Morgan Wealth Management Flint, Michigan $203M AUM 24.74% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Connective Capital Management's BIOC Position: Q1 2023 in Review

Connective Capital Management sold out of Biocept, Inc. (BIOC) in Q1 2023, closing a stake of 3,609 shares — an estimated $57.4K sold.

Connective Capital Management first reported a position in BIOC in Q4 2022 and held it in 1 quarter. The position peaked at $57.4K in Q4 2022. 25 funds tracked by Wall St. Rank hold BIOC as of Q1 2023.

  • Connective Capital Management reported no remaining Biocept, Inc. position as of Q1 2023 after selling out during the quarter.
  • Connective Capital Management sold 3,609 Biocept, Inc. shares in Q1 2023, an estimated $57.4K.
  • Connective Capital Management first reported a position in Biocept, Inc. in Q4 2022 and held it in 1 quarter.
  • Connective Capital Management's Biocept, Inc. position peaked at $57.4K in Q4 2022.
  • 25 funds tracked by Wall St. Rank held Biocept, Inc. as of Q1 2023.

Based on Connective Capital Management's 13F filing for Q1 2023, filed 17 May 2024.